Abstract:
A KLK gene as a tumor marker and method for diagnosing hepatocellular carcinoma are provided to obtain a novel diagnosis marker and research specific anticancer drug. A method for diagnosing hepatocellular carcinoma comprises: a step of measuring level of KLK-5 gene from a biological sample isolated from a patient with suspected hepatocellular carcinoma and protein level of the gene; and a step of comparing the expression levels of gene and protein between normal control sample and patient sample.
Abstract:
A hepatocellular carcinoma diagnostic kit containing a lipocalin 2 gene or their fraction and antibody is provided to increase the accuracy of the liver cancer diagnosis by performing the analysis by using the overexpression phenomenon of LCN2 in tissue, cells or body fluid of hepatocellular carcinoma patients. A hepatocellular carcinoma diagnostic kit comprises an antibody which is specifically bonded with the LCN2 protein. The hepatocellular carcinoma diagnostic kit comprises SEQ ID NO:3 which is specifically bonded with LCN2 mRNA or the nucleotide of SEQ ID NO:4. The hepatocellular carcinoma is diagnosed with the increment of the LCN2 protein amount. The mRNA quantity detection method uses RT-PCR(Reverse transcription polymerase chain reaction), competitive RT-PCR, realtime RT-PCR, RNase protection assay, Nothern blotting or DNA chip.
Abstract translation:提供含有脂质运载蛋白2基因或其部分和抗体的肝细胞癌诊断试剂盒,通过使用LCN2在肝细胞癌患者的组织,细胞或体液中的过表达现象进行分析,提高肝癌诊断的准确性。 肝细胞癌诊断试剂盒包括与LCN2蛋白特异性结合的抗体。 肝细胞癌诊断试剂盒包含与LCN2 mRNA特异性结合的SEQ ID NO:3或SEQ ID NO:4的核苷酸。 诊断为肝细胞癌的LCN2蛋白量增加。 mRNA量检测方法采用RT-PCR(逆转录聚合酶链反应),竞争性RT-PCR,实时RT-PCR,RNA酶保护试验,Nothern印迹法或DNA芯片。
Abstract:
본 발명은 경쟁반응에 의한 알파1산 당단백질측정방법과 측정용 킷트 및 알파1산 당단백질과 아사이알로 알파1산 당단백질의 농도의 비율을 측정하여 간질환을 진단하는 방법으로, 본 발명의 측정방법과 측정용 킷트는 간경화, 간암 등 간 질환의 조기진단과 치료성과의 평가에 유용하게 사용할 수 있으며, 다량의 시료를 동시에 재현성 있고 정확하게 측정할 수 있는 장점이 있다. 아시알로 알파1산 당단백질, 알파1산 당단백질, 간질환, 진단, 킷트
Abstract:
A method for diagnosing hepatic diseases is provided to diagnose the hepatic diseases reproducibly and accurately by using a concentration ratio of an alpha1-acid glycoprotein to an asialo-alpha1-acid glycoprotein in blood. A kit for diagnosing the hepatic diseases is provided to perform the method conveniently and rapidly. A method for diagnosing hepatic diseases comprises the steps of: (a) measuring a concentration of an alpha1-acid glycoprotein in a serum sample; (b) measuring a concentration of an asialo-alpha1-acid glycoprotein in the serum sample; and (c) diagnosing the hepatic disease when a value calculated by dividing the concentration of the alpha1-acid glycoprotein in the serum sample into the concentration of the asialo-alpha1-acid glycoprotein in the serum sample is more than 10%. A kit for diagnosing the hepatic diseases comprises: (a) a first kit including a solid phase body where an antibody regarding an alpha1-acid glycoprotein is absorbed, a biotinylated alpha1-acid glycoprotein, a strepavidine solution coupled to an enzyme, a diluted solution of a serum sample, an enzyme substrate solution, a washing solution and an alpha1-acid glycoprotein standard solution; and a second kit including a solid phase body where an antibody regarding an asialo alpha1-acid glycoprotein is absorbed, an Armoracia rusticana peroxidase-RCA conjugate solution, an ortho-phenylenediamine(OPD) substrate solution, a serum diluted solution and an asialo-glycoprotein standard solution.